1338831-06-3

Upstream product

• 13123-92-7 (2,4-dichlorophenyl)hydrazine 
• 106103-85-9 2-(2-(2,4-dichlorophenyl)hydrazono)acetic acid 

Downstream Products

• 1259007-21-0 N-(2,4-dichlorophenyl)-2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamide 
• 1259007-22-1 N-(2-chloropyridin-3-yl)-2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamide 
• 1259007-23-2 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-(4-methyl-2-nitrophenyl)acetamide 
• 1259007-24-3 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-(2-nitrophenyl)acetamide 
• 1259007-25-4 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-o-tolylacetamide 
• 1259007-26-5 N-(4-acetyl-2-bromophenyl)-2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamide 
• 1259007-27-6 N-(2-bromo-4-methylphenyl)-2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamide 
• 1259007-28-7 N-(2-bromo-4-chlorophenyl)-2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamide 
• 1259007-29-8 methyl 3-bromo-4-(2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamido)benzoate 
• 1259007-30-1 ethyl 3-bromo-4-(2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamido)benzoate 
• 1259007-31-2 methyl 4-(2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamido)benzoate 
• 1338831-07-4 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetic acid 
• 1259007-18-5 N-(2-chlorophenyl)-2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)acetamide 
• 1259007-19-6 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-(2-fluorophenyl)acetamide 

Relevant academic research and scientific papers

Arylazolylthioacetanilide. Part 8*: Design, synthesis and biological evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3- ylthio)-N-arylacetamides As Potent HIV-1 inhibitors

The development of novel HIV-1 NNRTIs offers the possibility of generating novel structures with increased potency. Based on the bioisosteric principle, a novel series of 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamide derivatives were designed, synthesized using a simple and efficient synthetic route, structurally confirmed by spectral analysis, evaluated for their anti-HIV activity in MT-4 cells and their inhibitory effect on HIV-1 RT. The results showed that some of the new compounds displayed low micromolar potency for inhibiting HIV-1 replication and promising activities against several selected resistant strains that confer resistance to current NNRTIs. However, all newly synthesized derivatives were not active against HIV-2 replication.